T lymphocyte responses against hepatitis B virus-related hepatocellular carcinoma induced by adenovirus vaccine encoding HBx

International Journal of Molecular Medicine

Volumn 26, Issue 6, 2010, Pages 869-876

  Li, Yuhua ^a,b   Cheng, Ping ^a   Wen, Yanjun ^a   Chen, Ping ^a,b   Yang, Li ^a   Zhao, Xia ^a   Lv, Huimin ^a   Quan, Qingli ^a   Wu, Yonglin ^b   Yang, Huiqiang ^b   Liu, Jie ^b   Wen, Xueru ^b   Liu, Nina ^b   Kang, Zhuang ^b   Luo, Shan ^a,b   Wang, Lian ^b   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

CTLs; HBx; Hepatitis B virus; Hepatocellular carcinoma; Immunotherapy

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; HEPATITIS B VIRUS X PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EMBRYO; FEMALE; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VIVO STUDY; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR NECROSIS; TUMOR VOLUME; VALIDITY; VIRUS REPLICATION;

ADENOVIRIDAE; ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HEK293 CELLS; HEPATITIS B VIRUS; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICROSCOPY, FLUORESCENCE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANS-ACTIVATORS; TRANSFECTION;

EID: 78649915734     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000536     Document Type: Article

References (32)

1. Bouchard MJ and Schneider RJ: The enigmatic X gene of hepatitis B virus. J Virol 78: 12725-12734, 2004.
2. Beasley RP: Rocks along the road to the control of HBV and HCC. Ann Epidemiol 19: 231-234, 2009.
3. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS and Adams DH: A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49: 124-132, 2009.
4. Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M and Qian Q: Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res 12: 6523-6531, 2006.
5. Avila MA, Berasain C, Sangro B and Prieto J: New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884, 2006.
6. Zhu AX: Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11: 790-800, 2006.
7. Inchauspé G and Michel ML: Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat 14 (Suppl 1): 97-103, 2007.
8. Loirat D, Lemonnier FA and Michel ML: Multiepitopic HLAA* 0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 165: 4748-4755, 2000.
9. Tangri S, Ishioka GY, Huang X, Sidney J, Southwood S, Fikes J and Sette A: Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 194: 833-846, 2001. (Pubitemid 32983018)
10. Lutzky VP, Corban M, Heslop L, Morrison LE, Crooks P, Hall DF, Coman WB, Thomson SA and Moss DJ: Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine. J Virol 84: 407-417, 2010.
11. zu Putlitz J, Encke J and Wands JR: Cytotoxic T cell responses against hepatitis B virus polymerase induced by genetic immunization. J Hepatol 33: 986-991, 2000.
12. Tang H, Oishi N, Kaneko S and Murakami S: Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 97: 977-983, 2006. (Pubitemid 44322542)
13. Bouchard MJ, Wang L and Schneider RJ: Activation of focal adhesion kinase by hepatitis B virus HBx protein: multiple functions in viral replication. J Virol 80: 4406-4414, 2006.
14. Wang WL, London WT and Feitelson MA: Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 51: 4971-4977, 1991.
15. + T cells in xenografted nude mice. J Immunol 170: 1183-1190, 2003.
16. Ding FX, Wang F, Lu YM, Li K, Wang KH, He XW and Sun SH: Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 49: 1492-1502, 2009.
17. Wang YJ, Hou Y, Huang H, Liu GR, White AP and Liu SL: Two oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunity. Cancer Lett 263: 67-76, 2008.
18. Cheng P, Li Y, Yang L, Wen Y, Shi W, Mao Y, Chen P, Lv H, Tang Q and Wei Y: Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase. Oncol Rep 22: 1101-1107, 2009.
19. Li G, Tian L, Hou JM, Ding ZY, He QM, Feng P, Wen YJ, Xiao F, Yao B, Zhang R, Peng F, Jiang Y, Luo F, Zhao X, Zhang L, Zhou Q and Wei YQ: Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 11: 4217-4224, 2005.
20. Zhao JM, Wen YJ, Li Q, Wang YS, Wu HB, Xu JR, Chen XC, Wu Y, Fan LY, Yang HS, Liu T, Ding ZY, Du XB, Diao P, Li J, Wu HB, Kan B, Lei S, Deng HX, Mao YQ, Zhao X and Wei YQ: A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J 22: 4272-4280, 2008.
21. Lu Y, Wei YQ, Tian L, Zhao X, Yang L, Hu B, Kan B, Wen YJ, Liu F, Deng HX, Li J, Mao YQ, Lei S, Huang MJ, Peng F, Jiang Y, Zhou H, Zhou LQ and Luo F: Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 170: 3162-3170, 2003.
22. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou YY, Huang MJ, Xiao F, Liu JY, Hu B, Luo F, Jiang Y, Wen YJ, Deng HX, Li J, Niu T and Yang JL: Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 278: 21831-21836, 2003.
23. Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F, Jiang Y, Hu B, Wu Y, Su JM, Lou YY, He QM, Wen YJ, Yang JL, Kan B, Mao YQ, Luo F and Peng F: Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102: 1815-1823, 2003.
24. Ganem D and Varmus HE: The molecular biology of the hepatitis B viruses. Annu Rev Biochem 56: 651-693, 1987.
25. Chisari FV and Ferrari C: Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13: 29-60, 1995.
26. Dandri M, Schirmacher P and Rogler CE: Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication. J Virol 70: 5246-5254, 1996. (Pubitemid 26240697)
27. Su Q, Schröder CH, Hofmann WJ, Otto G, Pichlmayr R and Bannasch P: Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology 27: 1109-1120, 1998.
28. Duraiswamy J, Bharadwaj M, Tellam J, Connolly G, Cooper L, Moss D, Thomson S, Yotnda P and Khanna R: Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res 64: 1483-1489, 2004.
29. Basner-Tschakarjan E, Gaffal E, O'Keeffe M, Tormo D, Limmer A, Wagner H, Hochrein H and Tüting T: Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production. J Gene Med 8: 1300-1306, 2006. (Pubitemid 44782509)
30. Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD and Levy R: Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 97: 1370-1377, 2001.
31. Armstrong AC, Dermime S, Allinson CG, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL and Hawkins RE: Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 168: 3983-3991, 2002. (Pubitemid 34298403)
32. Wong CP and Levy R: Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma. Cancer Res 60: 2689-2695, 2000.